Abstract
There has been ample data providing a convincing perception about the underlying mechanism pertaining to left ventricle (LV) hypertrophy progressing towards LV failure. In comparison, data available on the feedback of right ventricle (RV) due to volume or pressure overload is minimal. Advanced imaging techniques have aided the study of physiology, anatomy, and diseased state of RV. However, the treatment scenario of right ventricular failure (RVF) demands more attention. It is a critical clinical risk in patients with carcinoid syndrome, pulmonary hypertension, atrial septal defect, and several other concomitant diseases. Although the remodeling responses of both ventricles on an increase of end-diastolic pressure are mostly identical, the stressed RV becomes more prone to oxidative stress activating the apoptotic mechanism with diminished angiogenesis. This instigates the advancement of RV towards failure in contrast to LV. Empirical heart failure (HF) therapies have been ineffective in improving the mortality rate and cardiac function in patients, which prompted a difference between the underlying pathophysiology of RVF and LV failure. Treatment strategies should be devised, taking into consideration the anatomical and physiological characteristics of RV. This review would emphasize on the pathophysiology of the RVF and the differences between two ventricles in molecular response to stress. A proper insight into the underlying pathophysiology is required to develop optimized therapeutic management in RV-specific HF.
Similar content being viewed by others
Availability of data and material
Not applicable.
Code availability
Not applicable.
References
Raina A, Meeran T (2018) Right ventricular dysfunction and its contribution to morbidity and mortality in left ventricular heart failure. Curr Heart Fail Rep 15:94–105
Kormos RL, Teuteberg JJ, Pagani FD et al (2010) Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 139:1316–1324
LaRue SJ, Raymer DS, Pierce BR et al (2017) Clinical outcomes associated with INTERMACS-defined right heart failure after left ventricular assist device implantation. J Hear Lung Transplant 36:475–477
Galiè N, Humbert M, Vachiery J-L et al (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endor. Eur Heart J 37:67–119
Greyson CR (2008) Pathophysiology of right ventricular failure. Crit Care Med 36:S57–S65
Zapol WM, Snider MT (1977) Pulmonary hypertension in severe acute respiratory failure. N Engl J Med 296:476–480
Lambermont B, Ghuysen A, Kolh P et al (2003) Effects of endotoxic shock on right ventricular systolic function and mechanical efficiency. Cardiovasc Res 59:412–418
Arrigo M, Huber LC, Winnik S et al (2019) Right ventricular failure: pathophysiology, diagnosis and treatment. Card Fail Rev 5:140
Stobierska-Dzierzek B, Awad H, Michler RE (2001) The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 38:923–931
Kaul TK, Fields BL (2000) Postoperative acute refractory right ventricular failure: incidence, pathogenesis, management and prognosis. Cardiovasc Surg 8:1–9
La Vecchia L, Zanolla L, Varotto L et al (2001) Reduced right ventricular ejection fraction as a marker for idiopathic dilated cardiomyopathy compared with ischemic left ventricular dysfunction. Am Heart J 142:181–189
Goldstein JA (2002) Pathophysiology and management of right heart ischemia. J Am Coll Cardiol 40:841–853
Nieminen MS, Brutsaert D, Dickstein K et al (2006) EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27:2725–2736
Bristow MR, Kao DP, Breathett KK et al (2017) Structural and functional phenotyping of the failing heart: is the left ventricular ejection fraction obsolete? JACC Hear Fail 5:772–781. https://doi.org/10.1016/j.jchf.2017.09.009
Simonneau G, Galiè N, Rubin LJ et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:S5–S12. https://doi.org/10.1016/j.jacc.2004.02.037
Melenovsky V, Hwang SJ, Lin G et al (2014) Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 35:3452–3462. https://doi.org/10.1093/eurheartj/ehu193
McIntyre KM, Sasahara AA (1977) The ratio of pulmonary arterial pressure to pulmonary vascular obstruction: index of preembolic cardiopulmonary status. Chest 71:692–697
Wrobel JP, Thompson BR, Williams TJ (2012) Mechanisms of pulmonary hypertension in chronic obstructive pulmonary disease: a pathophysiologic review. J Hear Lung Transplant 31:557–564
Arrigo M, Huber LC (2013) Eponyms in cardiopulmonary reflexes. Am J Cardiol 112:449–453
Weitzenblum E (2003) Chronic cor pulmonale. Heart 89:225–230
Hilde JM, Skjørten I, Grøtta OJ et al (2013) Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension. J Am Coll Cardiol 62:1103–1111
Haigney MC, Zareba W, Gentlesk PJ et al (2004) QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADUT) II patients. J Am Coll Cardiol 44:1481–1487. https://doi.org/10.1016/j.jacc.2004.06.063
Spaan JAE, Piek JJ, Hoffman JIE, Siebes M (2006) Physiological basis of clinically used coronary hemodynamic indices. Circulation 113:446–455. https://doi.org/10.1161/CIRCULATIONAHA.105.587196
Kasner M, Westermann D, Steendijk P et al (2012) Left ventricular dysfunction induced by nonsevere idiopathic pulmonary arterial hypertension: a pressure-volume relationship study. Am J Respir Crit Care Med 186:181–189. https://doi.org/10.1164/rccm.201110-1860OC
Gorter TM, van Veldhuisen DJ, Bauersachs J et al (2018) Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20:16–37. https://doi.org/10.1002/ejhf.1029
Srivaratharajah K, Coutinho T, Dekemp R et al (2016) Reduced myocardial flow in heart failure patients with preserved ejection fraction. Circ Hear Fail 9:1–9. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002562
Thenappan T, Shah SJ, Gomberg-Maitland M et al (2011) Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Hear Fail 4:257–265. https://doi.org/10.1161/CIRCHEARTFAILURE.110.958801
Rosenson RS, Brewer HB, Davidson WS et al (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125:1905–1919. https://doi.org/10.1161/CIRCULATIONAHA.111.066589
Minai OA, Ricaurte B, Kaw R et al (2009) Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 104:1300–1306. https://doi.org/10.1016/J.AMJCARD.2009.06.048
Bosch L, Lam CSP, Gong L et al (2017) Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. Eur J Heart Fail 19:1664–1671. https://doi.org/10.1002/ejhf.873
Chang PP, Longenecker JC, Wang NY et al (2005) Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. J Hear Lung Transplant 24:998–1007. https://doi.org/10.1016/J.HEALUN.2004.07.013
Gorter TM, van Melle JP, Rienstra M et al (2018) Right heart dysfunction in heart failure with preserved ejection fraction: the impact of atrial fibrillation. J Card Fail 24:177–185. https://doi.org/10.1016/J.CARDFAIL.2017.11.005
Zornoff LAM, Skali H, Pfeffer MA et al (2002) Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol 39:1450–1455. https://doi.org/10.1016/S0735-1097(02)01804-1
Ghio S, Guazzi M, Scardovi AB et al (2017) Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail 19:873–879. https://doi.org/10.1002/ejhf.664
Pfisterer M, Emmenegger H, Müller-Brand J, Burkart F (1990) Prevalence and extent of right ventricular dysfunction after myocardial infarction — relation to location and extent of infarction and left ventricular function. Int J Cardiol 28:325–332. https://doi.org/10.1016/0167-5273(90)90315-V
Abraityte A, Lunde IG, Askevold ET et al (2017) Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy. Sci Rep 7:1–10. https://doi.org/10.1038/s41598-017-03625-9
Griepp RB, Stinson EB, Dong E et al (1971) Determinants of operative risk in human heart transplantation. Am J Surg 122:192–197. https://doi.org/10.1016/0002-9610(71)90316-3
Gude E, Simonsen S, Geiran OR et al (2010) Pulmonary hypertension in heart transplantation: discrepant prognostic impact of pre-operative compared with 1-year post-operative right heart hemodynamics. J Hear Lung Transplant 29:216–223. https://doi.org/10.1016/J.HEALUN.2009.08.021
Bittner HB, Chen EP, Biswas SS et al (1999) Right ventricular dysfunction after cardiac transplantation: primarily related to status of donor heart. Ann Thorac Surg 68:1605–1611. https://doi.org/10.1016/S0003-4975(99)00987-X
Carrier M, Blaise G, Bélisle S et al (1999) Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation. J Hear Lung Transplant 18:664–667. https://doi.org/10.1016/S1053-2498(99)00025-X
Raina A, Vaidya A, Gertz ZM et al (2013) Marked changes in right ventricular contractile pattern after cardiothoracic surgery: implications for post-surgical assessment of right ventricular function. J Hear Lung Transplant 32:777–783. https://doi.org/10.1016/J.HEALUN.2013.05.004
Fitzpatrick JR, Frederick JR, Hsu VM et al (2008) Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Hear Lung Transplant 27:1286–1292. https://doi.org/10.1016/J.HEALUN.2008.09.006
Drakos SG, Janicki L, Horne BD et al (2010) Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol 105:1030–1035. https://doi.org/10.1016/J.AMJCARD.2009.11.026
Schlossarek S, Carrier L (2011) The ubiquitin-proteasome system in cardiomyopathies. Curr Opin Cardiol 26:190–195. https://doi.org/10.1097/HCO.0b013e32834598fe
Naeije R, Brimioulle S, Dewachter L (2014) Biomechanics of the right ventricle in health and disease (2013 Grover Conference Series). Pulm Circ 4:395–406. https://doi.org/10.1086/677354
Puwanant S, Hamilton KK, Klodell CT et al (2008) Tricuspid annular motion as a predictor of severe right ventricular failure after left ventricular assist device implantation. J Hear Lung Transplant 27:1102–1107. https://doi.org/10.1016/J.HEALUN.2008.07.022
Vivo RP, Cordero-Reyes AM, Qamar U et al (2013) Increased right-to-left ventricle diameter ratio is a strong predictor of right ventricular failure after left ventricular assist device. J Hear Lung Transplant 32:792–799. https://doi.org/10.1016/J.HEALUN.2013.05.016
Kato TS, Farr M, Schulze PC et al (2012) Usefulness of two-dimensional echocardiographic parameters of the left side of the heart to predict right ventricular failure after left ventricular assist device implantation. Am J Cardiol 109:246–251. https://doi.org/10.1016/J.AMJCARD.2011.08.040
Denault AY, Couture P, Beaulieu Y et al (2015) Right ventricular depression after cardiopulmonary bypass for valvular surgery. J Cardiothorac Vasc Anesth 29:836–844. https://doi.org/10.1053/J.JVCA.2015.01.011
Kassis H, Cherukuri K, Agarwal R et al (2017) Significance of residual mitral regurgitation after continuous flow left ventricular assist device implantation. JACC Hear Fail 5:81–88. https://doi.org/10.1016/j.jchf.2016.09.014
Kiernan MS, French AL, Denofrio D et al (2015) Preoperative three-dimensional echocardiography to assess risk of right ventricular failure after left ventricular assist device surgery. J Card Fail 21:189–197. https://doi.org/10.1016/J.CARDFAIL.2014.12.009
Lampert BC, Teuteberg JJ (2015) Right ventricular failure after left ventricular assist devices. J Hear Lung Transplant 34:1123–1130. https://doi.org/10.1016/J.HEALUN.2015.06.015
Kapelios CJ, Charitos C, Kaldara E et al (2015) Late-onset right ventricular dysfunction after mechanical support by a continuous-flow left ventricular assist device. J Hear Lung Transplant 34:1604–1610. https://doi.org/10.1016/J.HEALUN.2015.05.024
Takeda K, Takayama H, Colombo PC et al (2015) Incidence and clinical significance of late right heart failure during continuous-flow left ventricular assist device support. J Hear Lung Transplant 34:1024–1032. https://doi.org/10.1016/J.HEALUN.2015.03.011
Pawlush DG, Musch TI, Moore RL (1989) Ca2+-dependent heterometric and homeometric autoregulation in hypertrophied rat heart. Am J Physiol Circ Physiol 256:H1139–H1147
Haddad F, Hunt SA, Rosenthal DN, Murphy DJ (2008) Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 117:1436–1448. https://doi.org/10.1161/CIRCULATIONAHA.107.653576
Marino TA, Kent RL, Uboh CE et al (1985) Structural analysis of pressure versus volume overload hypertrophy of cat right ventricle. Am J Physiol Circ Physiol 249:H371–H379
Moudgil R, Michelakis ED, Archer SL (2005) Hypoxic pulmonary vasoconstriction. J Appl Physiol 98:390–403
Schmitt J-M, Vieillard-Baron A, Augarde R et al (2001) Positive end-expiratory pressure titration in acute respiratory distress syndrome patients: impact on right ventricular outflow impedance evaluated by pulmonary artery Doppler flow velocity measurements. Crit Care Med 29:1154–1158
Vlahakes GJ, Turley K, Hoffman JIE (1981) The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation 63:87–95
Davlouros PA, Niwa K, Webb G, Gatzoulis MA (2006) The right ventricle in congenital heart disease. Heart 92:i27–i38
Reddy S, Bernstein D (2015) Molecular mechanisms of right ventricular failure. Circulation 132:1734–1742
Haddad F, Doyle R, Murphy DJ, Hunt SA (2008) Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 117:1717–1731
Raina A, Seetha Rammohan HR, Gertz ZM et al (2013) Postoperative right ventricular failure after left ventricular assist device placement is predicted by preoperative echocardiographic structural, hemodynamic, and functional parameters. J Card Fail 19:16–24. https://doi.org/10.1016/J.CARDFAIL.2012.11.001
Hoetzenecker K, Ankersmit HJ, Bonderman D et al (2009) Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report. J Thorac Cardiovasc Surg 137:760–761. https://doi.org/10.1016/j.jtcvs.2008.03.064
Piao L, Fang Y-H, Parikh KS et al (2012) GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation 126:2859–2869
Shaddy RE, Boucek MM, Hsu DT et al (2007) Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298:1171–1179
Rouleau JL, Kapuku G, Pelletier S et al (2001) Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway. Circulation 104:939–944
Nagaya N, Nishikimi T, Uematsu M et al (2000) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865–870
Ueno M, Miyauchi T, Sakai S et al (1999) Effects of physiological or pathological pressure load in vivo on myocardial expression of ET-1 and receptors. Am J Physiol Integr Comp Physiol 277:R1321–R1330
Voelkel NF, Quaife RA, Leinwand LA et al (2006) Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114:1883–1891. https://doi.org/10.1161/CIRCULATIONAHA.106.632208
Dessap AM, Leon R, Habibi A et al (2008) Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 177:646–653. https://doi.org/10.1164/rccm.200710-1606OC
Bogaard HJ, Abe K, Noordegmaf AV, Voelkel NF (2009) The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 135:794–804. https://doi.org/10.1378/CHEST.08-0492
Chan CM, Klinger JR (2008) The right ventricle in sepsis. Clin Chest Med 29:661–676. https://doi.org/10.1016/J.CCM.2008.07.002
Konstantinides S (2008) Acute pulmonary embolism. N Engl J Med 359:2804–2813. https://doi.org/10.1056/NEJMcp0804570
Skrupky LP, Kerby PW, Hotchkiss RS (2011) Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology 115:1349–1362. https://doi.org/10.1097/ALN.0b013e31823422e8
Meldrum DR (1998)Tumor necrosis factor in the heart. Am J Physiol 274. https://doi.org/10.1152/ajpregu.1998.274.3.r577
Gold FL, Bache RJ (1982) Transmural right ventricular blood flow during acute pulmonary artery hypertension in the sedated dog. Evidence for subendocardial ischemia despite residual vasodilator reserve. Circ Res 51:196–204
Zong P, Tune JD, Downey HF (2005) Mechanisms of oxygen demand/supply balance in the right ventricle. Exp Biol Med 230:507–519
Zamanian RT, Haddad F, Doyle RL, Weinacker AB (2007) Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 35:2037–2050. https://doi.org/10.1097/01.CCM.0000280433.74246.9E
Keogh AM, Mayer E, Benza RL et al (2009) Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 54:S67–S77. https://doi.org/10.1016/j.jacc.2009.04.016
Hoeper MM, Barberà JA, Channick RN et al (2009) Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 54:S85–S96. https://doi.org/10.1016/j.jacc.2009.04.008
Steele PM, Fuster V, Cohen M et al (1987) Isolated atrial septal defect with pulmonary vascular obstructive disease - long-term follow-up and prediction of outcome after surgical correction. Circulation 76:1037–1042. https://doi.org/10.1161/01.CIR.76.5.1037
La Vecchia L, Varotto L, Zanolla L et al (2006) Right ventricular function predicts transplant-free survival in idiopathic dilated cardiomyopathy. J Cardiovasc Med 7:706–710. https://doi.org/10.2459/01.JCM.0000243006.90170.ce
Pesto S, Begic Z, Prevljak S et al (2016) Pulmonary hypertension - new trends of diagnostic and therapy. Med Arch (Sarajevo, Bosnia Herzegovina) 70:303–307. https://doi.org/10.5455/medarh.2016.70.303-307
MacNee W (1994) State of the art pathophysiology of cor pulmonale in chronic obstrudive. Am J Respir Crit Care Med 150:833–852
Sztrymf B, Souza R, Bertoletti L et al (2010) Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 35:1286–1293. https://doi.org/10.1183/09031936.00070209
Reesink HJ, Tulevski II, Marcus JT et al (2007) Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 84:537–543. https://doi.org/10.1016/J.ATHORACSUR.2007.04.006
Lankeit M, Kempf T, Dellas C et al (2008) Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 177:1018–1025. https://doi.org/10.1164/rccm.200712-1786OC
Nickel N, Kempf T, Tapken H et al (2008) Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178:534–541. https://doi.org/10.1164/rccm.200802-235OC
Forfia PR, Fisher MR, Mathai SC et al (2006) Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 174:1034–1041. https://doi.org/10.1164/rccm.200604-547OC
Lega JC, Lacasse Y, Lakhal L, Provencher S (2009) Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax 64:869–875. https://doi.org/10.1136/thx.2008.110965
Forfia PR, Mathai SC, Fisher MR et al (2008) Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 177:1364–1369. https://doi.org/10.1164/rccm.200712-1876OC
Meluzín J, Špinarová L, Dušek L et al (2003) Prognostic importance of the right ventricular function assessed by Doppler tissue imaging. Eur J Echocardiogr 4:262–271. https://doi.org/10.1016/S1525-2167(02)00171-3
Tei C, Dujardin KS, Hodge DO et al (1996) Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 9:838–847. https://doi.org/10.1016/S0894-7317(96)90476-9
Fisher MR, Forfia PR, Chamera E et al (2009) Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179:615–621. https://doi.org/10.1164/rccm.200811-1691OC
Marik PE, Cavallazzi R, Vasu T, Hirani A (2009) Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. Crit Care Med 37:2642–2647. https://doi.org/10.1097/CCM.0b013e3181a590da
Monnet X, Rienzo M, Osman D et al (2006) Passive leg raising predicts fluid responsiveness in the critically ill. Crit Care Med 34:1402–1407. https://doi.org/10.1097/01.CCM.0000215453.11735.06
Suga H (2003) Cardiac energetics: from Emax to pressure–volume area. Clin Exp Pharmacol Physiol 30:580–585
Hebert PC, Wells G, Blajchman MA et al (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. J Urol 162:280–280. https://doi.org/10.1097/00005392-199907000-00110
Chen X, Zhu W, Tan J et al (2017) Early outcome of early-goal directed therapy for patients with sepsis or septic shock: a systematic review and meta-analysis of randomized controlled trials. Oncotarget 8:27510–27519. https://doi.org/10.18632/oncotarget.15550
Costanzo MR, Guglin ME, Saltzberg MT et al (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49:675–683. https://doi.org/10.1016/j.jacc.2006.07.073
Goldstein JA, Harada A, Yagi Y et al (1990) Hemodynamic importance of systolic ventricular interaction, augmented right atrial contractility and atrioventricular synchrony in acute right ventricular dysfunction. J Am Coll Cardiol 16:181–189. https://doi.org/10.1016/0735-1097(90)90477-7
Balanos GM, Talbot NP, Dorrington KL, Robbins PA (2003) Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography. J Appl Physiol 94:1543–1551. https://doi.org/10.1152/japplphysiol.00890.2002
Vieillard-Baron A, Jardin F (2003) Why protect the right ventricle in patients with acute respiratory distress syndrome? Curr Opin Crit Care 9:15–21. https://doi.org/10.1097/00075198-200302000-00004
Vieillard-Baron A, Charron C, Caille V et al (2007) Prone positioning unloads the right ventricle in severe ARDS. Chest 132:1440–1446. https://doi.org/10.1378/CHEST.07-1013
Roosens CD, Ama R, Leather HA et al (2006) Hemodynamic effects of different lung-protective ventilation strategies in closed-chest pigs with normal lungs. Crit Care Med 34:2990–2996. https://doi.org/10.1097/01.CCM.0000242758.37427.16
Fan E, Wilcox ME, Brower RG et al (2008) Recruitment maneuvers for acute lung injury: a systematic review. Am J Respir Crit Care Med 178:1156–1163. https://doi.org/10.1164/rccm.200802-335OC
Vizza CD, Della Rocca G, Roma DA et al (2001) Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care 5:355–361. https://doi.org/10.1186/cc1069
Kerbaul F, Rondelet B, Motte S et al (2004) Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 32:1035–1040. https://doi.org/10.1097/01.CCM.0000120052.77953.07
Angle MR, Molloy DW, Penner B et al (1989) The cardiopulmonary and renal hemodynamic effects of norepinephrine in canine pulmonary embolism. Chest 95:1333–1337. https://doi.org/10.1378/CHEST.95.6.1333
Chen EP, Bittner HB, Davis RD, Van Trigt P (1997) Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. Ann Thorac Surg 63:814–821. https://doi.org/10.1016/S0003-4975(97)00011-8
Hentschel T, Yin N, Riad A et al (2007) Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology 106:124–131. https://doi.org/10.1097/00000542-200701000-00021
Khazin V, Kaufman Y, Zabeeda D et al (2004) Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J Cardiothorac Vasc Anesth 18:156–159. https://doi.org/10.1053/J.JVCA.2004.01.020
Lamarche Y, Malo O, Thorin E et al (2005) Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 130:83–92. https://doi.org/10.1016/J.JTCVS.2004.09.011
Sebkhi A, Strange JW, Phillips SC et al (2003) Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107:3230–3235. https://doi.org/10.1161/01.CIR.0000074226.20466.B1
Tsai BM, Wang M, Pitcher JM et al (2005) Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone. Shock 24:417–420. https://doi.org/10.1097/01.shk.0000183390.98519.05
Schwartz BG, Levine LA, Comstock G et al (2012) Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol 59:9–15. https://doi.org/10.1016/j.jacc.2011.07.051
Kota B, Prasad AS, Economides C, Singh BN (2008) Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure. J Cardiovasc Pharmacol Ther 13:269–278. https://doi.org/10.1177/1074248408324550
Kopustinskiene DM, Pollesello P, Saris NEL (2001) Levosimendan is a mitochondrial KATP channel opener. Eur J Pharmacol 428:311–314. https://doi.org/10.1016/S0014-2999(01)01350-4
Morelli A, Teboul JL, Maggiore SM et al (2006) Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 34:2287–2293. https://doi.org/10.1097/01.CCM.0000230244.17174.4F
Parissis JT, Karavidas A, Bistola V et al (2008) Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis 197:278–282. https://doi.org/10.1016/J.ATHEROSCLEROSIS.2007.04.023
Missant C, Rex S, Segers P, Wouters PF (2007) Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med 35:707–715. https://doi.org/10.1097/01.ccm.0000257326.96342.57
Kaisers U, Busch T, Deja M et al (2003) Selective pulmonary vasodilation in acute respiratory distress syndrome. Crit Care Med 31:337–342. https://doi.org/10.1097/01.ccm.0000057913.45273.1a
Rossaint R, Gerlach H, Schmidt-Ruhnke H et al (1995) Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 107:1107–1115. https://doi.org/10.1378/CHEST.107.4.1107
Bhorade S, Christenson J, O’Connor M et al (1999) Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 159:571–579. https://doi.org/10.1164/ajrccm.159.2.9804127
Fattouch K, Sbraga F, Bianco G et al (2005) Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg 20:171–176. https://doi.org/10.1111/j.0886-0440.2005.200383w.x
Morrell ED, Tsai BM, Crisostomo PR et al (2006) Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. Shock 25:214–226. https://doi.org/10.1097/01.shk.0000191380.44972.46
Meldrum DR, Shames BD, Meng X et al (1998) Nitric oxide downregulates lung macrophage inflammatory cytokine production. Ann Thorac Surg 66:313–317. https://doi.org/10.1016/S0003-4975(98)00525-6
Solina A, Papp D, Ginsberg S et al (2000) A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth 14:12–17. https://doi.org/10.1016/S1053-0770(00)90048-X
Christenson J, Lavoie A, O’Connor M et al (2000) The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med 161:1443–1449. https://doi.org/10.1164/ajrccm.161.5.9806138
Reichenberger F, Pepke-Zaba J, McNeil K et al (2004) Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Heart 90:69. https://doi.org/10.1136/heart.90.1.69
Dodson MW, Brown LM, Elliott CG (2018) Pulmonary arterial hypertension. Heart Fail Clin 14:255–269. https://doi.org/10.1016/j.hfc.2018.02.003
Acknowledgements
We thankfully acknowledge the support extended by Mr. Manoj L. Yellurkar and Mr. Vani Sai Prasanna in literature collection.
Author information
Authors and Affiliations
Contributions
Idea for the article: Dr. Somasundaram Arumugam. Literature search: Dr. Somasundaram Arumugam, Pamelika Das. Manuscript writing: Pamelika Das. Critical revision of the work: Dr. Somasundaram Arumugam, Dr. Rajarajan A. Thandavarayan, Dr. Kenichi Watanabe, Dr. Ravichandiran Velayutham.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Das, P., Thandavarayan, R.A., Watanabe, K. et al. Right ventricular failure: a comorbidity or a clinical emergency?. Heart Fail Rev 27, 1779–1793 (2022). https://doi.org/10.1007/s10741-021-10192-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-021-10192-9